ReachMD CME
ReachMD
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.
Location:
Fort Washington, PA
Genres:
Health & Wellness Podcasts
Networks:
ReachMD
Description:
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.
Language:
English
Website:
http://www.reachmd.com/cme.aspx
Differentiating and Managing Pneumonitis in Unresectable Stage III NSCLC: Case Discussion
Duration:00:05:59
Optimizing Consolidative Immunotherapy in Unresectable Stage III NSCLC: Case Discussion
Duration:00:05:29
Consolidative Immunotherapy in Unresectable Stage III NSCLC With Oncogenic Drivers
Duration:00:04:29
Immunotherapy Approaches in Unresectable Stage III NSCLC: What’s on the Horizon?
Duration:00:05:59
Chemoradiotherapy Toxicities: How Do They Impact Starting Immunotherapy?
Duration:00:05:29
Consolidative Immunotherapy Following sCRT vs RT Only in Stage III NSCLC
Duration:00:04:29
Consolidation Immunotherapy After Concurrent CRT: What Do Real-World Data Show?
Duration:00:04:00
Resolving Practice Barriers to Consolidative Immunotherapy in Stage III NSCLC
Duration:00:05:29
Accurate Staging and Determining Resectability in NSCLC
Duration:00:04:59
Safety and Tolerability of Changing Covalent BTK Inhibitor Treatment in a Patient Intolerant to Ibrutinib or Acalabrutinib
Duration:00:05:29
Selection of BTK Inhibitor Following Frontline Chemoimmunotherapy in Older Patients With Comorbidities
Duration:00:05:30
Initial BTK Inhibitor-Based Treatment Selection in a Treatment-Naive, Symptomatic, Unfit Older Patient With Comorbidities and High-Risk Cytogenetics
Duration:00:05:27
Optimal Sequencing of ADCs in Endocrine Refractory HR+/HER2- Metastatic Breast Cancer
Duration:00:28:58
ATTR-CM Management: Pearls From Recent Clinical Trials and Tailoring Therapy
Duration:00:12:51
Are Two Pathways Better Than One? Experts Discuss the Role of Ang-2/VEGF-A Inhibition in Retinal Vascular Disease
Duration:00:56:56
Optimizing First-Line Immunotherapy for Recurrent or Metastatic HNSCC
Duration:00:05:59
Managing Immune-Related Adverse Events With Immunotherapies
Duration:00:05:59
Overcoming Barriers to Equitable Care in HNSCC
Duration:00:05:29
Current and Emerging Biomarkers of Response to Immunotherapeutic Regimens
Duration:00:06:00
The Role of Immunotherapy in the Treatment of Recurrent or Metastatic HNSCC: The Evidence
Duration:00:06:29